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Summary
 
A conserved subset of mature circulating T cells in humans expresses an invariant V
 
a
 
24-J
 
a
 
Q T
cell receptor (TCR)-
 
a
 
 chain rearrangement and several natural killer (NK) locus–encoded
C-type lectins. These human T cells appear to be precise homologues of the subset of NK1.1
 
1
 
TCR-
 
a/b
 
1
 
 T cells, often referred to as NK T cells, which was initially identified in mice. Here
we show that human NK T cell clones are strongly and specifically activated by the same syn-
thetic glycolipid antigens as have been shown recently to stimulate murine NK T cells. Re-
sponses of human NK T cells to these synthetic glycolipids, consisting of certain 
 
a
 
-anomeric
sugars conjugated to an acylated phytosphingosine base, required presentation by antigen-pre-
senting cells expressing the major histocompatibility complex class I–like CD1d protein. Pre-
sentation of synthetic glycolipid antigens to human NK T cells required internalization of the
glycolipids by the antigen-presenting cell and normal endosomal targeting of CD1d. Recogni-
tion of these compounds by human NK T cells triggered proliferation, cytokine release, and
cytotoxic activity. These results demonstrate a striking parallel in the specificity of NK T cells
in humans and mice, thus providing further insight into the potential mechanisms of immune
recognition by NK T cells and the immunological function of this unique T cell subset.
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N
 
atural killer (NK) T cells are a recently described sub-
population of TCR-
 
a/b
 
1
 
 CD4
 
1
 
 or CD4
 
2
 
8
 
2
 
 T lym-
phocytes that have distinctive phenotypic and functional
properties (1). These T cells were first identified in mice,
where they can be distinguished from conventional T cells
by their expression of the NK locus–encoded C-type lectin
molecule NK1. Another hallmark of murine NK T cells is
their extremely restricted TCR repertoire, with the great
majority expressing an invariant TCR-
 
a
 
 chain structure
(V
 
a
 
14-J
 
a
 
281) paired preferentially with V
 
b
 
8, 7, or 2 (2,
3). Recently, it has been demonstrated that the human im-
mune system contains a population of T cells that show
striking conservation of most of the key features of murine
NK T cells (4–6). These human NK T cells express an in-
variant V
 
a
 
24-J
 
a
 
Q TCR-
 
a
 
 chain, which is highly homol-
ogous to the invariant TCR-
 
a
 
 chain of murine NK T cells
(2). In addition, human NK T cells express a restricted V
 
b
 
repertoire (7, 8) and several NK locus–encoded C-type
lectins, including NKR-P1A (CD161), which is the ho-
mologue of murine NK1 (4).
At present, the function of NK T cells in the immune
response remains incompletely resolved. However, much
interest has been generated by the finding that murine and
human NK T cells are able to produce large amounts of
both IL-4 and IFN-
 
g
 
 rapidly upon activation, and may
represent a major source of early IL-4 in certain immune
responses (4, 9). Recent results also suggest major roles for
murine NK T cells in the rejection of malignant tumors
(10) and in regulating autoimmunity (11–13). Given these
potentially important activities of NK T cells, it has be-
come of great interest to resolve the question of what for-
eign or self-antigens these T cells recognize. Initial insight
into this question came with the finding that both murine
and human NK T cells are capable of specifically recogniz-
ing the MHC class I–like CD1d protein (4, 14). As other
members of the CD1 family have recently been shown to
mediate the presentation of foreign lipids and glycolipids to
T cells (15–17), this suggested the possibility that the actual
target ligands of NK T cells may be CD1 proteins that have
bound foreign or endogenous lipids.
Recently, Kawano et al. reported the CD1-dependent
recognition of a family of synthetic glycolipid antigens by
murine NK T cells, thus providing the first insight into the
structure of foreign antigens recognized by this T cell sub-
set (18). The glycolipids that were active in their experi-
ments were composed of an 
 
a
 
-anomeric sugar linked to a
ceramide type acylphytosphingosine (APS) lipid, and are
structurally related but distinct from the abundant ceramide-
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containing glycolipids (e.g., gangliosides) found in normal
mammalian tissues (19). In this study, we show that human
CD1d-restricted T cells also respond to these 
 
a
 
-glycosyl-
APS, and have a fine specificity for different compounds in
this family that is remarkably similar to that shown for
mouse NK T cells. Recognition of these synthetic gly-
colipids was restricted exclusively by human CD1d, as
other members of the human CD1 family (CD1a, -b, and -c)
were unable to present these antigens to human NK T
cells. Our results provide further evidence for the conserva-
tion of a functional NK T cell subset in humans, and sup-
port the hypothesis that the immunological role of these T
cells involves recognition of foreign or endogenous gly-
colipids.
 
Materials and Methods
 
Human NK T Cell Clones and CD1 Transfectants.
 
Human NK
T cell clones DN2.B9, DN2.C7, and DN2.D5 were derived,
maintained, and phenotypically analyzed as previously described
(4, 8). The cervical carcinoma cell line HeLa was transfected with
the expression vector pSR
 
a
 
-Neo containing cDNA inserts en-
coding CD1a, CD1b, CD1c, or CD1d according to previously
described methods (20). The HeLa CD1d/a transfectant ex-
pressed a chimeric form of CD1d with the extracellular domains
of CD1d fused to the transmembrane plus cytoplasmic domains
of CD1a. This stable transfectant was produced by the introduc-
tion into HeLa cells of a previously described expression con-
struct encoding this chimeric protein (4).
 
T Cell Proliferation Assays.
 
5 
 
3 
 
10
 
4
 
 T cells were plated in
triplicate in flat-bottomed 96-well plate wells with 10
 
4
 
 mitomy-
cin C–treated APCs (0.1 mg/ml for 1 h at 37
 
8
 
C; Sigma Chemical
Co., St. Louis, MO). Media for all T cell cultures was RPMI
1640 (GIBCO BRL, Gaithersburg, MD) plus 10% fetal bovine
serum (HyClone Labs., Logan, UT) and other additives as previ-
ously detailed (21). The synthetic glycolipid antigens used in this
study were provided by the Pharmaceutical Research Laboratory,
Kirin Brewery Co., Ltd. (Gunma, Japan), and have been de-
scribed in detail previously (18). Although these were previously
designated as glycosyl-ceramides, here we have referred to them
as glycosyl-APS derivatives because of the hydroxylations of the
third and fourth carbons in their sphingosine base that are charac-
teristic of phytosphingosines (19). Synthetic glycolipids were dis-
solved at 100 
 
m
 
g/ml in DMSO, and diluted into culture medium
to the indicated final concentrations. For mAb blocking experi-
ments, the following mAbs were added as purified IgG to a final
concentration of 20 
 
m
 
g/ml: W6/32 (anti-HLA-A, -B, and -C;
reference 22); CD1d51 (anti-CD1d; reference 4); and P3 (non-
binding IgG1 control; reference 23). For light fixation of the
APC surface, CD1d-transfected HeLa cells were incubated for
1 h on ice in 2 ml of 0.9% NaCl containing 75 mM 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide-HCl (ECDI; Pierce Chemi-
cal Co., Rockford, IL), followed by extensive washing in RPMI
1640 medium. Cultures were incubated at 37
 
8
 
C in a 5% CO
 
2
 
 in-
cubator, pulsed with 1 
 
m
 
Ci of [
 
3
 
H]thymidine (2 Ci/mmol) on
day 2 and harvested 16 h later for 
 
b
 
 scintillation counting using a
Tomtec harvester and a Betaplate scintillation counter (Wallac,
Gaithersburg, MD).
 
Cytokine and Cytotoxic T Cell Assays.
 
5 
 
3
 
 10
 
4
 
 T cells were
cultured in triplicate wells with 10
 
4
 
 mitomycin C–treated CD1d-
transfected HeLa cells in the absence or presence of 100 ng/ml
of 
 
a
 
-galactosyl-APS (
 
a
 
GalAPS). Phytohemagglutinin (PHA-P;
Difco, Detroit, MI) was added to some cultures (1:2,000 final di-
lution) as a positive control. Supernatants were harvested after 48 h,
and cytokine levels determined by capture ELISA as described
(4). T cell cytotoxic activity was measured using a standard 4-h
 
51
 
Cr-release assay (21). Mock-transfected or CD1d-transfected
HeLa cells were labeled with 200 
 
m
 
Ci of 
 
51
 
Cr for 2 h at 37
 
8
 
C,
followed by incubation for 12 h at 37
 
8
 
C in complete medium
with or without 200 ng/ml of 
 
a
 
GalAPS, and then washed and
used as target cells. Assays were performed in triplicate and results
were expressed as percentage of maximum specific 
 
51
 
Cr release.
 
Results and Discussion
 
Specific Recognition of Synthetic Glycolipid Antigens by Hu-
man NK T Cell Clones.
 
Three previously characterized hu-
man NK T clones (DN2.B9, DN2.C7, and DN2.D5; ref-
erence 4) bearing the invariant V
 
a
 
24-J
 
a
 
Q TCR-
 
a
 
 chain
paired with different V
 
b
 
11
 
1
 
 TCR-
 
b
 
 chains were tested for
their ability to respond to synthetic APS-containing gly-
colipid antigens presented by CD1d-transfected HeLa cells.
Because human NK T cells generally have intrinsic autore-
activity to CD1d-expressing cells (4), modifications of the
culture conditions were required for optimal demonstra-
tion of the response to synthetic glycolipids. Preliminary
experiments (data not shown) revealed that CD1d-trans-
fected HeLa cells were particularly suited as APCs for these
studies, since they did not require additional exogenous
signals such as PMA to support the proliferation of human
NK T cells. Using a relatively low APC/T cell ratio (1:5),
we observed low to moderate autoreactivity and consistent
augmentation of the proliferation of human NK T cells
clones when the synthetic glycolipid 
 
a
 
GalAPS was added
(Fig. 1 
 
a
 
).
The response to 
 
a
 
GalAPS appeared to be specific for
NK T cell clones, since this compound did not stimulate
proliferation of a panel of other human T cell clones that
did not express the invariant V
 
a
 
24-J
 
a
 
Q TCR-
 
a
 
 chain
(data not shown). The specificity of the response to syn-
thetic glycolipids was also assessed by examining the re-
sponses of NK T cell clones to a panel of structurally related
glycolipids. These included two previously demonstrated
strong stimulators of murine NK T cells (
 
a
 
GalAPS and
 
a
 
GluAPS), as well as four related analogues that were non-
stimulatory or weakly stimulatory in the murine system
(APS, 
 
a
 
ManAPS, 
 
b
 
GalAPS, and 3,4-deoxy 
 
a
 
GalAPS)
(18). NK T cell clones responded strongly to 
 
a
 
GalAPS and
 
a
 
GluAPS but not to the other analogues (Fig. 1 
 
b
 
, and ad-
ditional data not shown), demonstrating a pattern very sim-
ilar to that observed for murine NK T cells. Thus, the spe-
cific recognition of synthetic glycolipids by a human NK T
cell clone required an 
 
a
 
-anomeric sugar (either galactose or
glucose) and the presence of hydroxylations at positions 3
and 4 of the phytosphingosine base, exactly as described for
murine NK T cells.
 
CD1 Restriction of Synthetic Glycolipid Recognition by Hu-
man NK T Cells.
 
In mice, two CD1 genes encode ex-
tremely homologous proteins, both of which are most 
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closely related to human CD1d. In contrast, humans have a
more diversified family of CD1 proteins, with genes en-
coding five distinct isoforms designated CD1a, -b, -c, -d,
and -e (24). Previous work has shown that the human
CD1d protein is a target for direct recognition by human
NK T cell clones (4), whereas CD1a, -b, and -c present
lipid and glycolipid antigens to other populations of T cells
(15–17, 21). To determine if the human NK T cell re-
sponse to 
 
a
 
-glycosyl-APS was restricted only by the CD1d
protein, or if other human CD1 isoforms could also sup-
port this response, we tested the ability of HeLa cells stably
transfected with each of the human CD1 proteins to
present 
 
a
 
GalAPS. For all three human NK T cell clones
tested, the response to 
 
a
 
GalAPS was seen only when
CD1d
 
1
 
 HeLa cells were used as APCs (Fig. 2 
 
a
 
 and data
not shown). Confirmation of this CD1d-restriction was
obtained by mAb blocking experiments, which demon-
strated that an mAb against the cell surface expressed con-
formation of CD1d protein (CD1d51) significantly inhib-
ited the response to 
 
a
 
GalAPS (Fig. 2 
 
b
 
). Thus, responses of
human NK T cells to glycosyl-APS derivatives were de-
pendent on APC expression of CD1, and CD1d was the
only human CD1 isoform that presented these glycolipids
to NK T cells.
Figure 1. Human NK T cell clones specifically respond to synthetic
glycolipid antigens. (a) Proliferative responses of three different human
NK T cell clones to CD1d-transfected HeLa cell APCs were significantly
augmented by addition of the synthetic glycolipid aGalAPS. White bars
show proliferation in response to CD1d1 HeLa cells plus vehicle
(DMSO) alone; black bars show proliferation in response to CD1d1
HeLa cells plus 100 ng/ml aGalAPS. Results are shown as the mean and
one standard deviation of triplicate values in this and all subsequent fig-
ures. (b) Proliferative responses of human NK T cell clone DN2.C7 to a
panel of structurally related synthetic glycolipid antigens. APS is the non-
glycosylated acyl-phytosphingosine lipid. aGalAPS, aGluAPS, and
aManAPS indicate compounds in which a-anomeric galactose, glucose,
and mannose, respectively are conjugated at position 1 of the hexose ring
to the APS moiety. 3,4-deoxy aGalAPS is identical to aGalAPS except
for the absence of the hydroxyl groups on carbons 3 and 4 of the
phytosphingosine base. For complete structures of the synthetic glycolip-
ids, see Kawano et al. (18). Thymidine incorporation in the absence of
synthetic glycolipid antigen was 500 cpm in the experiment shown.
Figure 2. CD1d dependence of synthetic glycolipid antigen recogni-
tion by human NK T cells. (a) Response of human NK T cell clone
DN2.C7 to aGalAPS (100 ng/ml) in the presence of HeLa cells not ex-
pressing CD1 (transfected with vector alone; mock) or expressing each of
the known protein isoforms of human CD1. T cell proliferation in the
absence of aGalAPS is shown by the white bars, and in the presence of
aGalAPS by the black bars. Identical results were obtained with two
other human NK T cell clones, DN2.B9 and DN2.D5 (data not shown).
(b) Inhibition of aGalAPS-stimulated proliferation of human NK T cell
clone DN2.B9 by anti-CD1d mAb. Results are shown as the percentage
of inhibition of the aGalAPS-dependent proliferation in the presence of
CD1d1 HeLa cells. With no antibody present, proliferation in the pres-
ence of the aGalAPS was 3,900 cpm, and in the absence of aGalAPS was
,200 cpm in the experiment shown. Marginal blocking was observed
with anti–MHC class I mAb W6/32 in some experiments. This was also
seen in parallel experiments using MHC class II–restricted T cell clones
(data not shown), and thus most likely represents a nonspecific effect of
this antibody.1532 Glycolipid-reactive Human NK T Cells
Requirements for Uptake and Endosomal Loading of Synthetic
Glyclolipid Antigens. To determine if antigen internaliza-
tion by CD1d1 APCs was required for presentation, we
examined the effects of blocking plasma membrane traf-
ficking by light chemical fixation of APCs. Because alde-
hyde fixatives caused strong augmentation of the autoreac-
tivity of human NK T cells to CD1d1 APCs (4), we
instead used the chemical cross-linker ECDI as a fixative
(25). CD1d1 HeLa cells were surface cross-linked by ECDI
either before or after a 12-h pulse with aGalAPS (100 ng/
ml), and then tested for their ability to stimulate prolifera-
tion of clone DN2.C7. Whereas APCs treated with ECDI
after the antigen pulse stimulated strong proliferation of
DN2.C7, fixation with ECDI before antigen pulsing com-
pletely abrogated the response to aGalAPS (Fig. 3 a). This
strongly suggested a requirement for antigen uptake by
APCs in the response to this synthetic glycolipid.
Consistent with this requirement for antigen uptake,
studies of aGalAPS presentation to murine NK T cells
have demonstrated that this process is inhibited by chloro-
quine, and thus may require endosomal acidification (18).
To further examine this possibility, we assessed the ability
of a modified form of human CD1d that is deficient in en-
dosomal localization to present aGalAPS. Human CD1d,
like CD1b and CD1c but not CD1a, has a short cytoplas-
mic tail containing a tyrosine-based four-amino acid motif
(24). For CD1b, this motif has been shown to be critical
for endosomal localization and efficient microbial lipid an-
Figure 3. Requirement for antigen uptake and endosomal delivery of
CD1d in recognition of synthetic glycolipids by human NK T cells. (a)
Proliferative responses of clone DN2.C7 to ECDI-fixed APCs. CD1d1
HeLa cells either were pulsed for 12 h with aGalAPS (100 ng/ml) and
subsequently fixed by ECDI treatment, or were fixed first followed by
aGalAPS pulsing. White bars represent APCs pulsed with vehicle
(DMSO) alone, and black bars represent APCs pulsed with aGalAPS. (b)
Proliferation of clone DN2.C7 to aGalAPS presented by HeLa cell trans-
fectants expressing wild-type CD1d (circles) versus HeLa transfectants ex-
pressing the CD1d/a chimeric protein that lacks an endosomal targeting
signal (squares). Both transfectants expressed comparable levels of immu-
noreactive CD1d on the cell surface. Proliferation in the absence of APCs
was ,200 cpm in this experiment. Note that DN2.C7 showed a weak
but significant response to the CD1d/a transfectant in the absence of
added antigen, but no augmentation of this response at any concentration
of aGalAPS tested.
Figure 4. Activation of effector functions of human NK T cells by syn-
thetic glycolipid antigens. (a) Stimulation of IL-4 and IFN-g secretion by
aGalAPS. Human NK T cell clones were cultured with CD1d-express-
ing HeLa cells in the presence (white bars) or absence (black bars) of aGal-
APS (100 ng/ml) or with PHA (hatched bars), and supernatants were har-
vested after 48 h and assayed for cytokines by ELISA. No cytokine
production was detected in cultures containing T cells only or CD1d-
transfected HeLa cells only (data not shown). (b) Human NK T cell
clones specifically lysed CD1d-transfected HeLa cells pulsed for 12 h with
aGalAPS (200 ng/ml). No lysis was observed using mock-transfected
HeLa cells as targets (data not shown).1533 Spada et al. Brief Definitive Report
tigen presentation by this molecule (20). Previously, we
generated a chimeric form of the human CD1d protein in
which the CD1d ectodomains are fused to transmembrane
and cytoplasmic domains of CD1a, eliminating the endoso-
mal targeting signal normally present in CD1d. Previous
studies with this construct expressed in B lymphoblastoid
cells showed that the chimeric CD1d/a protein was defec-
tive in endosomal localization, but was well expressed on
the cell surface (4). To assess the importance of endosomal
delivery of CD1d, we examined the dose response of clone
DN2.C7 to aGalAPS presented by HeLa cells expressing
either wild-type CD1d or the CD1d/a chimera. This re-
vealed a striking effect of the deletion of the targeting mo-
tif, essentially abolishing the ability of CD1d/a to present
aGalAPS (Fig. 3 b). This finding, along with the require-
ment for antigen internalization by the APCs, strongly sug-
gested that synthetic glycolipid antigens colocalize with
CD1d in the endocytic system, and that this is required for
the generation of a complex that is recognized by NK T
cells on the APC surface.
Functional Consequences of CD1d-restricted Presentation of
Synthetic Glycolipids. A hallmark of both murine and hu-
man NK T cells has been their ability to rapidly produce
cytokines associated with both Th1 (IFN-g) and Th2 (IL-
4) responses upon TCR engagement (1, 4, 11). Interest-
ingly, however, it has been noted that several conditions
exist in which this apparent Th0 profile of cytokine pro-
duction may be skewed either toward a predominance of
IFN-g (11, 26) or of IL-4 (14, 27). We found that stimula-
tion with aGalAPS generated substantial levels of both
IFN-g and IL-4 by the three human NK T cell clones
tested (Fig. 4 a, and data not shown). Some variation be-
tween clones in the relative amounts of IFN-g and IL-4
production was observed, but in all cases the cytokine pro-
duction mirrored that observed with activation by PHA.
Human NK T cell clones also showed enhanced cytotoxic
activity against CD1d1 HeLa cells pulsed with aGalAPS
(Fig. 4 b). Thus, CD1d-restricted recognition of aGalAPS
augmented the known effector functions of human NK T
cell clones, and preserved their Th0 pattern of cytokine se-
cretion.
Our results demonstrated CD1d-restricted recognition
of synthetic glycosyl-APS by human NK T cells, and con-
firmed the striking conservation of this T cell subset be-
tween humans and mice in both phenotype and function.
The presentation of synthetic glycolipids by CD1d also
supports the growing body of data demonstrating that the
main function of CD1 proteins may be the presentation of
foreign microbial lipid and glycolipid antigens (15–17, 21).
In spite of this substantial progress, the main immunologi-
cal functions of NK T cells remain unclear. The synthetic
glycolipids used in this study are not yet known to have
precise counterparts in relevant infectious agents, and the
prototype natural compounds in this family were originally
isolated not from microbial pathogens but from marine
sponges (18). Nevertheless, given the impressive antitumor
effects of NK T cells and a variety of studies indicating that
they may play a role in regulating autoimmune inflamma-
tory diseases, the discovery of exogenous ligands that can
modulate the activity of this unique T cell subset is of great
potential importance. Our results demonstrating that syn-
thetic glycosyl-APS derivatives are active modulators of the
human NK T cell system suggests that these compounds
may be promising candidates for immunotherapy of human
diseases.
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